Ranibizumab treatment in groups I and II was superior to vPDT based on mean average BCVA change from baseline to month @ through month @ ( group I : +@ , group II : +@ vs. group III : +@ Early Treatment Diabetic Retinopathy Study -LSB- ETDRS -RSB- letters ; both P < @ ) .